Sorrento Therapeutics Inc (SRNE)

[cheynew]

1:15p ET 8/4/2021 - Dow Jones
Sorrento Up 2% on Salicyn-30 Article
Mentioned: SRNE

By Josh Beckerman

Sorrento Therapeutics Inc. shares were recently up 2% to $8.35 after the company discussed an article about "promising results" for Salicyn-30 in a rodent model.

Sorrento, in collaboration with The Scripps Research Institute of La Jolla, said the American Chemical Society published "Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model."

An analysis in a prophylactic mouse model of SARS-CoV-2 infection "demonstrated that Salicyn-30 can potentially reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in Covid-19 infections," the company said.

Write to Josh Beckerman at [e-mail]

(END) Dow Jones Newswires

August 04, 2021 13:15 ET (17:15 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.